.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

ALTACE Drug Profile

« Back to Dashboard
Altace is a drug marketed by King Pharms and King Pfizer and is included in two NDAs. It is available from two suppliers. There is one patent protecting this drug.

This drug has forty-three patent family members in thirty-one countries.

The generic ingredient in ALTACE is ramipril. There are nineteen drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the ramipril profile page.

Summary for Tradename: ALTACE

Patents:1
Applicants:2
NDAs:2
Suppliers / Packagers: see list2
Drug Prices: :see details

Pharmacology for Tradename: ALTACE

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
King Pharms
ALTACE
ramipril
CAPSULE;ORAL019901-001Jan 28, 1991RXNo7,368,469► subscribe ► subscribe
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-003Feb 27, 2007DISCNNo7,368,469► subscribe ► subscribe
King Pharms
ALTACE
ramipril
CAPSULE;ORAL019901-004Jan 28, 1991RXYes7,368,469► subscribe ► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ALTACE

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
King Pharms
ALTACE
ramipril
CAPSULE;ORAL019901-004Jan 28, 19915,061,722► subscribe
King Pfizer
ALTACE
ramipril
TABLET;ORAL022021-002Feb 27, 20075,061,722► subscribe
King Pharms
ALTACE
ramipril
CAPSULE;ORAL019901-001Jan 28, 19914,587,258► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ALTACE

Country Document Number Estimated Expiration
South Korea20120055730► subscribe
World Intellectual Property Organization (WIPO)0115674► subscribe
Poland353199► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ALTACE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
80030Netherlands► subscribePRODUCT NAME: FELODIPINE, DESGEWENST IN DE VORM VAN FYSIOLOGISCH AANVAARDBAAR ZOUT, EN (2S, 3AS, 6AS)-1-[(S)-N-[(S)-1-CARBOXY-3-FENYLPROPYL]A LANYL]OCTAHYDROCYCLOPENTA[B]-PYRROOL-2-CARBONZUUR (RAMIPRILAAT) , DESGEWENST IN DE VORM VAN EEN .....ZIE VERDER IN HET DOSSIER; NAT. REGISTRATION NO/ DATE: RVG 22449, RVG 22450 19980618; FIRST REGISTRATION: SE 13596, 13597 19970919
C0001Belgium► subscribePRODUCT NAME: FELODIPINUM + RAMIPRILUM; NATL. REGISTRATION NO/DATE: 354 IS 373 F 3 19981103; FIRST REGISTRATION: SE 13597 19970919
C/GB98/047United Kingdom► subscribePRODUCT NAME: COMBINATIONS OF RAMIPRIL, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF, AND FELODIPINE, OR A PHYSIOLOGICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: SE 13596 19970919; SE 13597 19970919; UK 00017/0402 19980825; UK 00017/0403 19980825
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc